Brought to you by 
Arrowhead Research nets $35.4mm through common and preferred stock offering
09 May 2013
Executive Summary
With a $9.6mm investment, RA Capital has led a $35.4mm offering by Arrowhead Research Corp. (targeted drug delivery of peptide-drug conjugates and RNAi therapeutics for cancer, obesity, and HBV) of common and convertible preferred stock.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Other
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arrowhead Research nets $35.4mm through common and preferred stock offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice